No connection

Search Results

AKBA vs IRD

AKBA
Akebia Therapeutics, Inc.
BEARISH
Price
$1.46
Market Cap
$391.1M
Sector
Healthcare
AI Confidence
85%
IRD
Opus Genetics, Inc.
BEARISH
Price
$5.36
Market Cap
$381.4M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
AKBA
--
IRD
--
Forward P/E
AKBA
-15.37
IRD
-9.43
P/B Ratio
AKBA
11.87
IRD
24.36
P/S Ratio
AKBA
1.66
IRD
26.86
EV/EBITDA
AKBA
14.85
IRD
-8.75

Profitability

Gross Margin
AKBA
82.92%
IRD
-117.05%
Operating Margin
AKBA
-10.5%
IRD
-296.33%
Profit Margin
AKBA
-2.26%
IRD
0.0%
ROE
AKBA
--
IRD
-242.41%
ROA
AKBA
5.44%
IRD
-55.39%

Growth

Revenue Growth
AKBA
23.9%
IRD
-10.2%
Earnings Growth
AKBA
--
IRD
--

Financial Health

Debt/Equity
AKBA
6.1
IRD
0.07
Current Ratio
AKBA
1.55
IRD
6.43
Quick Ratio
AKBA
1.42
IRD
6.2

Dividends

Dividend Yield
AKBA
--
IRD
--
Payout Ratio
AKBA
0.0%
IRD
0.0%

AI Verdict

AKBA BEARISH

AKBA's Advanced Deterministic Scorecard reveals significant financial distress signals: a Piotroski F-Score of 2/9 indicates weak operational and financial health, while the absence of an Altman Z-Score raises bankruptcy risk concerns. Despite strong revenue growth (23.9% YoY) and a high gross margin (82.92%), the company operates at a net loss with negative profit and operating margins, and carries a dangerously high debt/equity ratio of 6.10. Insider selling activity totaling $0.90M over six months, including large sales by executives and the CEO, reinforces bearish sentiment. The stock trades at a premium valuation (Price/Sales: 1.66, Price/Book: 11.87) despite negative earnings and no intrinsic value support, making it vulnerable to downside pressure.

Strengths
Strong revenue growth of 23.9% YoY
High gross margin of 82.92% indicates pricing power or low production costs
Positive recent quarterly earnings surprises (average +53.7% over last 4 quarters)
Risks
Piotroski F-Score of 2/9 indicates severe financial and operational weakness
Debt/Equity ratio of 6.10 is extremely high, signaling financial leverage risk
Negative net profit margin (-2.26%) and operating margin (-10.50%) despite revenue growth
IRD BEARISH

The company exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. Most alarming is the negative gross margin of -117.05%, meaning the company loses money on every unit of revenue generated before operating expenses. Despite a speculative 654.9% price surge over the last year and a 'strong_buy' analyst consensus, the underlying data shows declining revenue (-10.20%) and extreme valuation multiples (P/B of 24.36). The stock appears to be trading on momentum or speculative expectations rather than any tangible financial health.

Strengths
Very low Debt/Equity ratio (0.07)
Strong short-term liquidity (Current Ratio 6.43)
Significant 1-year price momentum (+654.9%)
Risks
Negative gross margins (-117.05%) indicate a non-viable cost structure
Severe operational losses (Operating Margin -296.33%)
Declining revenue growth (-10.20% YoY)

Compare Another Pair

AKBA vs IRD: Head-to-Head Comparison

This page compares Akebia Therapeutics, Inc. (AKBA) and Opus Genetics, Inc. (IRD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile